Motus GI Hlds

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in 2008 and is headquartered in Fort Lauderdale, FL.

FORT LAUDERDALE, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Company's Pure-Vu® GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies.

Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management

FORT LAUDERDALE, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its third quarter 2020 financial results on Thursday, November 12, 2020, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Third Quarter 2020 Results and Provide a Business Update on November 12

FORT LAUDERDALE, Fla., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it will host a key opinion leader (KOL) call on improving inpatient endoscopy outcomes with the Pure-Vu® system on Friday, October 16, 2020.

Motus GI Hosting Key Opinion Leader Call on Improving Endoscopy Outcomes with the Pure-Vu® System

FORT LAUDERDALE, Fla., Sept.  14, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the China National Intellectual Property Administration ("CNIPA") issued patent 201680002365, titled “Distal Front End for Coordination Positioning of an Endoscope with a Suction Device.” The patent covers the method of mounting Motus GI’s proprietary sensing technology and enhanced suction systems with the distal end of a colonoscope. This patent further protects the Company’s flagship product – the Pure-Vu® System – in this key potential market.

Motus GI Expands Intellectual Property Portfolio with Chinese Patent for its Method to Mount the Pure-Vu® System on the End of a Colonoscope

FORT LAUDERDALE, Fla., Sept.  10, 2020  (GLOBE NEWSWIRE) --  Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to be presenting at the following upcoming virtual investor conferences:

Motus GI Scheduled to Present at Investor Conferences in September 2020

FORT LAUDERDALE, Fla., Aug.  28, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has entered into a securities purchase agreement with a single healthcare focused institutional investor providing for the sale and issuance of  8,733,625 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) at an effective purchase price of $1.145 per share of common stock (or $1.144 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to result in gross proceeds to Motus GI of approximately $10 million.  The closing of the offering is subject to customary closing conditions and is expected to close on or about September 1, 2020.

Motus GI Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market

Motus GI Holdings, Inc.'s (MOTS) CEO Tim Moran on Q2 2020 Results - Earnings Call Transcript

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 28.57% and -95.00%, respectively, for the quarter ended June 2020.

Motus GI Holdings, Inc. (MOTS) Reports Q2 Loss, Lags Revenue Estimates

Shares of Motus GI Hldgs (NASDAQ: MOTS) were flat after the company reported Q2 results.

Recap: Motus GI Hldgs Q2 Earnings

FORT LAUDERDALE, Fla., July  21, 2020  (GLOBE NEWSWIRE) --  Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Second Quarter 2020 Results and Provide a Business Update on August 11th

FORT LAUDERDALE, Fla., June  15, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced that physicians and hospitals using the Pure-Vu® System will now have on-demand access to a full spectrum of Motus support and educational resources via the new Motus GI mobile app, which was launched today. This new mobile solution is a part of a larger effort to diversify and digitize much of the go-to-market content for the Pure-Vu System, which is being adopted by a growing number of major U.S. hospitals since being commercially launched at the end of 2019.

Motus GI Launches Mobile App to Provide On-Demand Support and Resources to Hospitals Using the Pure-Vu® System

Live moderated video webcast discussion with CEO, Tim Moran on Monday, June 15, at 2:00 PM ET, immediately followed by an interactive Q&A session Live moderated video webcast discussion with CEO, Tim Moran on Monday, June 15, at 2:00 PM ET, immediately followed by an interactive Q&A session

Motus GI to Present at the Virtual Investor Fireside Chat Series

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q1 2020 Results - Earnings Call Transcript

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of -4.55% and -81.33%, respectively, for the quarter ended March 2020.

Motus GI Holdings, Inc. (MOTS) Reports Q1 Loss, Misses Revenue Estimates

FORT LAUDERDALE, Fla., May  14, 2020  (GLOBE NEWSWIRE) --  Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the first quarter ended March 31, 2020, and provided a corporate update.

Motus GI Reports First Quarter 2020 Financial Results and Provides Corporate Update

FORT LAUDERDALE, Fla., May  05, 2020  (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10646108 titled “Ancillary vacuum module usable with an endoscope”, which protects the Company’s flagship product – the Pure-Vu® System. The patent covers the integration of Motus GI’s proprietary sensing technology and enhanced suction systems with a colonoscope’s working channel.

Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the  Pure-Vu® System’s Sensing Technology and Suction Control

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q4 2019 Results - Earnings Call Transcript

FORT LAUDERDALE, Fla., March  30, 2020  (GLOBE NEWSWIRE) --  Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter and year ended December 31, 2019, and provided a corporate update.

Motus GI Reports Fourth Quarter and Year End 2019 Financial Results and Provides Corporate Update

As of late, it has definitely been a great time to be an investor in Motus GI Holdings.

Will Motus GI Continue to Surge Higher?

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q3 2019 Results - Earnings Call Transcript

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 28.00% and -97.00%, respectively, for the quarter ended September 2019.

Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Lags Revenue Estimates

Coherus BioSciences

DD3 Acquisition Corp - Units (1 Ord & 1 War)

Floor & Decor Holdings

HD Supply Hlds

Karuna Therapeutics Inc

OncoCyte

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

News for Motus GI Hlds Stock (MOTS)